Pricing & Access· July 10, 2026 · 21 min read
AstraZeneca Portfolio Dossier: Farxiga Cliff, Enhertu Pivot, and Soliris Conversion
By Ran Chen#Orange Book#Purple Book#Medicare Part D
Topic
Specialty Drugs
High-cost specialty medications, payer coverage, access barriers, utilization management, and manufacturer support programs.
Pricing & Access· July 7, 2026 · 17 min read
BMS Portfolio Dossier: The Eliquis Cliff, Opdivo Lifecycle, and Cobenfy Bet
By Ran Chen#Orange Book#Purple Book#Medicare Part D
Pricing & Access· July 6, 2026 · 16 min read
Merck Portfolio Dossier: Keytruda QLEX, the Januvia Cliff, and a Post-2028 Pipeline
By Ran Chen#Purple Book#Orange Book#Biosimilars
Pricing & Access· June 24, 2026 · 25 min read
Amgen Portfolio Dossier: Purple Book Biologics and Biosimilars
By Ran Chen#Purple Book#Biosimilars#Drug Pricing
Pricing & Access· June 24, 2026 · 25 min read
Eli Lilly Portfolio Dossier: Diabetes, Obesity, and Insulin Pricing
Pricing & Access· June 24, 2026 · 25 min read
Novartis Portfolio Dossier: Spinoff Splits and Patent Cliffs
By Ran Chen#Orange Book#Purple Book#Generics
Pricing & Access· June 24, 2026 · 26 min read
Pfizer Portfolio Dossier: Patent Cliffs, Shortages, and Recalls
By Ran Chen#Orange Book#Purple Book#FDA Approval
Approvals· June 7, 2026 · 8 min read
Imfinzi + BCG for NMIBC access guide: FDA approval, coding, and buy-and-bill
By Ran Chen#Oncology#PD-L1#Prior Authorization
Pricing & Access· June 6, 2026 · 14 min read
Aetna GLP-1 coverage: PA criteria, formulary tiers, and 2026 plan rules
By Ran Chen#GLP-1#Aetna#Prior Authorization
Pricing & Access· June 6, 2026 · 11 min read